Pharmacogenomic landscape of COVID-19 therapies from Indian population genomes

Aim: Numerous drugs are being widely prescribed for COVID-19 treatment without any direct evidence for the drug safety/efficacy in patients across diverse ethnic populations. Materials & methods: We analyzed whole genomes of 1029 Indian individuals (IndiGen) to understand the extent of drug–gene...

Descripción completa

Detalles Bibliográficos
Autores principales: Sahana, S, Sivadas, Ambily, Mangla, Mohit, Jain, Abhinav, Bhoyar, Rahul C, Pandhare, Kavita, Mishra, Anushree, Sharma, Disha, Imran, Mohamed, Senthivel, Vigneshwar, Divakar, Mohit Kumar, Rophina, Mercy, Jolly, Bani, Batra, Arushi, Sharma, Sumit, Siwach, Sanjay, Jadhao, Arun G, Palande, Nikhil V, Jha, Ganga Nath, Ashrafi, Nishat, Mishra, Prashant Kumar, Vidhya, AK, Jain, Suman, Dash, Debasis, Kumar, Nachimuthu Senthil, Vanlallawma, Andrew, Sarma, Ranjan Jyoti, Chhakchhuak, Lalchhandama, Kalyanaraman, Shantaraman, Mahadevan, Radha, Kandasamy, Sunitha, Devi, Pabitha, Rajagopal, Raskin Erusan, Ramya, J Ezhil, Devi, P Nirmala, Bajaj, Anjali, Gupta, Vishu, Mathew, Samatha, Goswami, Sangam, Prakash, Savinitha, Joshi, Kandarp, Kumla, Meya, Sreedevi, S, Gajjar, Devarshi, Soraisham, Ronibala, Yadav, Rohit, Devi, Yumnam Silla, Gupta, Aayush, Mukerji, Mitali, Ramalingam, Sivaprakash, Binukumar, BK, Sivasubbu, Sridhar, Scaria, Vinod
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216321/
https://www.ncbi.nlm.nih.gov/pubmed/34142560
http://dx.doi.org/10.2217/pgs-2021-0028
Descripción
Sumario:Aim: Numerous drugs are being widely prescribed for COVID-19 treatment without any direct evidence for the drug safety/efficacy in patients across diverse ethnic populations. Materials & methods: We analyzed whole genomes of 1029 Indian individuals (IndiGen) to understand the extent of drug–gene (pharmacogenetic), drug–drug and drug–drug–gene interactions associated with COVID-19 therapy in the Indian population. Results: We identified 30 clinically significant pharmacogenetic variants and 73 predicted deleterious pharmacogenetic variants. COVID-19-associated pharmacogenes were substantially overlapped with those of metabolic disorder therapeutics. CYP3A4, ABCB1 and ALB are the most shared pharmacogenes. Fifteen COVID-19 therapeutics were predicted as likely drug–drug interaction candidates when used with four CYP inhibitor drugs. Conclusion: Our findings provide actionable insights for future validation studies and improved clinical decisions for COVID-19 therapy in Indians.

Ejemplares similares